Erenumab effectively induces Medication Overuse Headache remission in chronic migraine patients. Monthly 140 mg injections ...

Monthly use of erenumab injections (140 mg) is safe and effective in achieving medication overuse headache (MOH) remission in ...

The comparative efficacy and tolerability of oral migraine medications suggest four triptans are superior to the newer, more ...

Over half of the cases of chronic daily headaches in adults are thought to be due to medication-overuse headache, and treatment consists of discontinuation of these analgesics. Since many patients ...

More information: Tepper, S. J. et al. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial, JAMA ...

85 The same study compared patients with medication overuse headache against healthy controls and showed that patients with medication overuse headache had a nonsignificant decrease in gray matter ...

A major new study has suggested the group of drugs called triptans are the most effective medicine for adults experiencing ...

Oxford University scientists reviewed 89,000 patients in clinical trials given 17 different pills for migraine attacks and ...

Rebound headaches, also called medication-overuse headaches, are caused by the excessive use of acute (short-term) headache medication in people with a prior history of headaches, usually migraine ...

In this study, monthly, 140 mg erenumab injections safely and effectively achieved medication overuse headaches remission in patients with nonopioid chronic migraine and medication overuse headaches ...

Headache type classified as part of the diagnosis. Information provision on the risk of medication overuse headache Not referring for imaging if patients do not have signs of symptoms of secondary ...

Too much, or too little, caffeine can make your migraines way worse—and that's a fact. But why do caffeine headaches even exist in the first place? And is there anything you can eat/drink/meditate on ...